Product and process for T lymphocyte immunosuppression
AssigneeNational Jewish Medical and Research Center
InventorUwe D. Staerz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a product and process for suppressing an immune response using a T lymphocyte veto molecule capable of blocking cell surface molecules responsible for T cell activation. Disclosed is a CD4 or CD2 molecule, associated with an immunoglobulin molecule capable of binding to a major histocompatibility antigen. Also disclosed is a method to produce a T lymphocyte veto molecule, a therapeutic composition comprising a T lymphocyte veto molecule and methods to use T lymphocyte veto molecules in therapeutic processes requiring suppression of an immune response.
Claims34
A T lymphocyte immunosuppression molecule comprising a chimeric molecule having a CD4 protein, wherein said protein is linked to a targeting immunoglobulin molecule that binds by its variable region to a molecule on the surface of a tissue graft cell that differentiates a host cell from said tissue graft cell.
A recombinant cell that expresses a chimeric T lymphocyte immunosuppression molecule, said recombinant cell having:
- (1) a first recombinant molecule comprising a first nucleic acid molecule operatively linked to an expression vector, said first nucleic acid molecule having a nucleic acid sequence encoding a first CD4 protein;
- and (2) a second recombinant molecule comprising a second nucleic acid molecule operatively linked to an expression vector, said second nucleic acid molecule having a nucleic acid sequence encoding a second protein comprising a targeting immunoglobulin molecule selected from the group consisting of a targeting immunoglobulin molecule having a variable region that binds to a tissue graft cell surface molecule that differentiates a host cell from a tissue graft cell and a targeting immunoglobulin molecule that selectively targets a molecule on the surface of a cell involved in an autoimmune response.
A composition comprising:
- a T lymphocyte immunosuppression molecule comprising:
- a chimeric molecule having a targeting immunoglobulin molecule selected from the group consisting of a targeting immunoglobulin molecule having a variable region that binds to a tissue graft cell surface molecule that differentiates a host cell from a tissue graft cell and a targeting immunoglobulin molecule having a variable region that selectively targets a molecule on the surface of a cell involved in an autoimmune response, wherein said targeting molecule is linked to a CD4 protein;
- and a pharmaceutically acceptable carrier.
A method for producing a T lymphocyte veto molecule, comprising:
- (a) providing a first protein comprising a CD4protein;
- (b) providing a second protein comprising a targeting immunoglobulin molecule selected from the group consisting of a targeting immunoglobulin molecule that binds to a tissue graft cell surface molecule that differentiates a host cell from a tissue graft cell and a targeting immunoglobulin molecule having a variable region that selectively targets a molecule on the surface of a cell involved in an autoimmune response;
- and
- (c) linking said first protein to said second protein to form a chimeric molecule.
A T lymphocyte immunosuppression molecule comprising a chimeric molecule having a CD4 protein;
- wherein said protein is linked to a targeting immunoglobulin that binds by its variable region to a molecule which selectively targets a cell involved in an autoimmune response.
A T lymphocyte immunosuppression molecule comprising a chimeric molecule having a CD4 protein, wherein said protein is linked to a monovalent targeting immunoglobulin molecule that binds by its variable region to a molecule on the surface of a cell selected from the group consisting of a tissue graft cell that differentiates a host cell from said tissue graft cell, and a cell involved in an autoimmune response.
Dependencies are inferred from the claim text.